Alpha Research: Aim's best biotech

Alpha Research: Aim's best biotech

Complex products and unfathomable acronyms used to name them often puts investors off the biotech sector. While the science under-pinning the companies is complex, by learning to make sense of their business models, equity investors need not dismiss a sector that has the potential to unearth some major winners. Of course, biotech investment should only ever contribute a small part of a well-diversified portfolio, but London's Aim market is currently abundant with exciting small- and mid-cap companies.  

To continue reading, subscribe to Alpha today

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now